ClinicalTrials.gg
RecruitingNCT06143956Updated Oct 7, 2026

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

A Phase 2 interventional study of LY3305677 and LY3841136 in Obesity and Overweight, sponsored by Eli Lilly and Company. Recruiting at 57 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Screening

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.
Updated Oct 7, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1,481
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing mazdutide in Obesity — 11 open to participants now, 14 under way, 4 of them phase 3. mazdutide · Obesity.

Planned enrollment
Largest of 22
1,481 · median 187
Started
2023
with 2 others
Phase 2
5 of 22
2 open now
Primary completion
2027-09
later than 5 of 13 live
Registered
6th of 22
by date
Lead sponsor
3 of 22
Eli Lilly and Company

Among the 22 studies testing mazdutide in Obesity, this one has the largest planned enrollment, is one of 3 that started in 2023, is one of 5 in phase 2, reaches primary completion later than 5 of the 13 other live ones, and was the 6th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

11 of the 22 studies testing mazdutide in Obesity are open now, in 3 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

About mazdutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing mazdutide in Obesity, or all of them as a file.
02

Study summary

The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newly enrolled participants across the master and the ISAs. The ISAs may start independently of other ISAs as interventions become available for clinical testing. The results for the CWMM screening record will be reported when all the ISA's complete.

03

Conditions studied

  • Obesity
  • Overweight
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a (BMI)

    • ≥30 kilogram/square meter (kg/m²), or
    • ≥27 kg/m² and \<30 kg/m², or with at least 1 weight-related comorbidity
  • Have had a stable body weight for the 3 months prior to randomization (\<5%) body weight gain and/or loss.

Exclusion criteria

Exclusion Criteria:

  • Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed >1 year prior to screening.
  • Have type 1 diabetes mellitus, latent diabetes in adults, or history of ketoacidosis or hyperosmolar coma.
  • Have poorly controlled hypertension.
  • Have signs and symptoms of any liver disease other than nonalcoholic fatty liver disease.
  • Have any of the following cardiovascular conditions within 3 months prior to screening:

    • acute myocardial infarction
    • cerebrovascular accident (stroke)
    • unstable angina, or
    • hospitalization due to congestive heart failure.
  • Have a history of symptomatic gallbladder disease within the past 2 years.
  • Have a lifetime history of suicide attempts.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,481 participants (estimated)

Study arms

  • Experimental
    LY3305677 Obesity ISA OXA1

    Participants will receive LY3305677 or placebo subcutaneously (SC). Each ISA will detail the intervention specific analysis.

    Drug: LY3305677 · Drug: Placebo

  • Experimental
    LY3841136 Obesity ISA LAA1

    Participants will receive LY3841136 or placebo SC. Each ISA will detail the intervention specific analysis.

    Drug: LY3841136 · Drug: Placebo

  • Experimental
    LY3841136 Obesity ISA LAA2

    Participants will receive LY3841136, tirzepatide and placebo SC. Each ISA will detail the intervention specific analysis.

    Drug: LY3841136 · Drug: Tirzepatide · Drug: Placebo

  • Experimental
    LY3549492 Obesity ISA GN01

    Participants will receive LY3549492 or placebo orally. Each ISA will detail the intervention specific analysis.

    Drug: LY3549492 · Drug: Placebo

  • Experimental
    LY3549492 Obesity ISA GN02

    Participants will receive LY3549492 or placebo orally. Each ISA will detail the intervention specific analysis.

    Drug: LY3549492 · Drug: Placebo

  • Experimental
    Obesity ISA MC01

    Participants will receive macupatide, eloralintide, and placebo SC. Each ISA will detail the intervention specific analysis.

    Drug: LY3841136 · Drug: LY3532226 · Drug: Placebo

Interventions

  • Administered SC. ISA specific interventions will be listed in the ISA.

  • Administered SC. ISA specific interventions will be listed in the ISA.

    Also known as: Eloralintide

  • Administered SC. ISA specific interventions will be listed in the ISA.

    Also known as: LY3298176

  • Administered orally. ISA specific interventions will be listed in the ISA.

  • Administered SC. ISA specific interventions will be listed in the ISA.

    Also known as: Macupatide

  • DrugPlacebo

    Administered SC. ISA specific interventions will be listed in the ISA.

  • DrugPlacebo

    Administered orally. ISA specific interventions will be listed in the ISA.

06

What researchers measure

Primary outcomes

  1. Number of Participants Allocated to Each ISA

    Each ISA will detail the intervention specific analysis.

    Time frame: Baseline to Week 6

07

Study locations

47 of 57 sites recruiting
  • The Institute for Liver Health II dba Arizona Clinical Trials - Mesa
    Chandler, Arizona 85225, United States
    Recruiting
    • Yessica Sachdeva · Principal investigator
  • HOPE Research Institute
    Phoenix, Arizona 85032, United States
    Completed

    Not enrolling at this site — choose another above.

  • Headlands Research - Scottsdale
    Scottsdale, Arizona 85260, United States
    Recruiting
    • · Contact480-725-8708
    • Benjamin Clark · Principal investigator
  • The Institute for Liver Health II dba Arizona Liver Health-Tucson
    Tucson, Arizona 85712, United States
    Recruiting
    • · Contact480-470-4000
    • Anita Kohli · Principal investigator
  • NorCal Medical Research, Inc
    Greenbrae, California 94904, United States
    Recruiting
    • · Contact415-461-1585
    • Linda Gaudiani · Principal investigator
  • Velocity Clinical Research, Huntington Park
    Huntington Park, California 90255, United States
    Recruiting
    • · Contact323-588-1990
    • Stanley Hsia · Principal investigator
  • Peninsula Research Associates
    Rolling Hills Estates, California 90274, United States
    Recruiting
    • · Contact310-265-1623
    • LeighAnn Schmidt · Principal investigator
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
    Recruiting
    • · Contact925-930-7267
    • Bonnie Kimmel · Principal investigator
  • Stamford Therapeutics Consortium
    Stamford, Connecticut 06905, United States
    Recruiting
    • David Radin · Principal investigator
  • Northeast Research Institute (NERI)
    Fleming Island, Florida 32003, United States
    Completed

    Not enrolling at this site — choose another above.

  • New Horizon Research Center
    Miami, Florida 33165, United States
    Recruiting
    • · Contact305-226-3933
    • Lazaro Nunez · Principal investigator
  • Indago Research & Health Center, Inc
    Miami Lakes, Florida 33016, United States
    Recruiting
    • · Contact305-825-6588
    • Jose Cardona · Principal investigator
  • Suncoast Clinical Research, Inc.
    New Port Richey, Florida 34652, United States
    Recruiting
    • · Contact727-849-4131
    • Cathy Barnes · Principal investigator
  • Charter Research - Winter Park
    Orlando, Florida 32803, United States
    Recruiting
    • · Contact407-337-3000
    • Edgardo Rivera-Rivera · Principal investigator
  • Charter Research - Lady Lake
    The Villages, Florida 32162, United States
    Recruiting
    • · Contact352-441-2000
    • Jeffrey Norton · Principal investigator
  • Pacific Diabetes & Endocrine Center
    Honolulu, Hawaii 96817, United States
    Completed

    Not enrolling at this site — choose another above.

  • Medical Research Partners
    Ammon, Idaho 83406, United States
    Recruiting
    • · Contact208-681-9070
    • Joseph Moore · Principal investigator
  • Great Lakes Clinical Trials - Ravenswood
    Chicago, Illinois 60640, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Great Lakes Clinical Trials - Ravenswood
    Chicago, Illinois 60640, United States
    Recruiting
    • · Contact773-275-3500 Ext 162
    • Rupal Trivedi · Principal investigator
  • NorthShore University Health System
    Skokie, Illinois 60077, United States
    Completed

    Not enrolling at this site — choose another above.

  • Iowa Diabetes and Endocrinology Research Center
    West Des Moines, Iowa 50266, United States
    Recruiting
    • · Contact515-329-6800
    • Anuj Bhargava · Principal investigator
  • Cotton O'Neil Diabetes & Endocrinology
    Topeka, Kansas 66606, United States
    Recruiting
    • · Contact785-354-9591
    • susan brian · Principal investigator
  • Monroe Biomedical Research - Louisville
    Louisville, Kentucky 40213, United States
    Recruiting
    • · Contact502-515-5672
    • Harold Bays · Principal investigator
  • Knownwell
    Needham, Massachusetts 02492, United States
    Recruiting
    • · Contact339-793-8998
    • Angela Fitch · Principal investigator
  • Lucida Clinical Trials
    New Bedford, Massachusetts 02740, United States
    Recruiting
    • · Contact508-720-2015
    • David Shih · Principal investigator
  • Headlands Research - Detroit
    Southfield, Michigan 48034, United States
    Recruiting
    • Christopher Romero · Principal investigator
  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
    Troy, Michigan 48098, United States
    Recruiting
    • · Contact248-312-0025
    • Neil Fraser · Principal investigator
  • StudyMetrix Research
    City of Saint Peters, Missouri 63303, United States
    Recruiting
    • · Contact636-387-5100
    • Timothy Smith · Principal investigator
  • Clinvest Headlands Llc
    Springfield, Missouri 65807, United States
    Recruiting
    • Christina Capps · Principal investigator
  • Las Vegas Medical Research
    Las Vegas, Nevada 89128, United States
    Recruiting
    • · Contact702-750-0000
    • Cornell Calinescu · Principal investigator
  • Dent Neurologic Institute
    Amherst, New York 14226, United States
    Recruiting
    • Laszlo Mechtler · Principal investigator
  • Velocity Clinical Research, Syracuse
    East Syracuse, New York 13057, United States
    Recruiting
    • Rachel Dubroff · Principal investigator
  • North Suffolk Neurology
    Port Jefferson Station, New York 11776, United States
    Completed

    Not enrolling at this site — choose another above.

  • Rochester Clinical Research, LLC
    Rochester, New York 14609, United States
    Recruiting
    • · Contact585-288-0890
    • Patrick Connors · Principal investigator
  • Medication Management
    Greensboro, North Carolina 27401, United States
    Recruiting
    • · Contact336-763-6968
    • James Franklin · Principal investigator
  • Monroe Biomedical Research
    Monroe, North Carolina 28112, United States
    Recruiting
    • · Contact704-283-7359
    • Awawu Igbinadolor · Principal investigator
  • Lucas Research, Inc
    Morehead City, North Carolina 28557, United States
    Recruiting
    • · Contact252-222-5700
    • Kathryn Lucas · Principal investigator
  • Lucas Research, Inc.
    New Bern, North Carolina 28562, United States
    Recruiting
    • · Contact252-649-1944
    • Joseph Maides · Principal investigator
  • CTI Clinical Research Center
    Cincinnati, Ohio 45212, United States
    Recruiting
    • · Contact513-721-3868
    • James Maynard · Principal investigator
  • Tribe Clinical Research, LLC
    Greenville, South Carolina 29607, United States
    Recruiting
    • · Contact864-334-0141
    • Ronald Mayfield · Principal investigator
  • Quality Medical Research
    Nashville, Tennessee 37211, United States
    Recruiting
    • · Contact615-835-4750
    • Saras Sharma · Principal investigator
  • IMA Clinical Research Austin
    Austin, Texas 78745, United States
    Recruiting
    • · Contact512-649-0082
    • Nomita Kim · Principal investigator
  • Velocity Clinical Research, Dallas
    Dallas, Texas 75230, United States
    Recruiting
    • Dan Lender · Principal investigator
  • FutureSearch Trials of Dallas
    Dallas, Texas 75251, United States
    Recruiting
    • · Contact214-369-2600
    • Michael Downing · Principal investigator
  • PlanIt Research, PLLC
    Houston, Texas 77079, United States
    Recruiting
    • · Contact713-973-3415
    • Amer Al-Karadsheh · Principal investigator
  • Endeavor Clinical Trials
    San Antonio, Texas 78240, United States
    Recruiting
    • · Contact518-428-6859
    • Nitendra Agarwal · Principal investigator
  • Tekton Research - Fredericksburg Road
    San Antonio, Texas 78258, United States
    Completed

    Not enrolling at this site — choose another above.

  • Texas Valley Clinical Research
    Weslaco, Texas 78596, United States
    Recruiting
    • · Contact956-431-8090
    • Eduardo Luna · Principal investigator
  • Sovah Clinical Research-River District
    Danville, Virginia 24541, United States
    Recruiting
    • · Contact434-793-4711
    • Stephan Jannach · Principal investigator
  • Central Washington Health Services Association d/b/a Confluence Health
    Wenatchee, Washington 98801, United States
    Recruiting
    • · Contact509-436-4050
    • Kathryn Eren · Principal investigator
  • Cicemo Srl
    Buenos Aires, 1424, Argentina
    Recruiting
    • · Contact5491157417654
    • Pablo Costanzo · Principal investigator
  • CARDIAMET Investigaciones Médicas
    Buenos Aires, C1014ACP, Argentina
    Not yet recruiting
    • · Contact5491165496764
    • Angela Romero Zarante · Principal investigator
  • Centro de Investigaciones Metabólicas (CINME)
    Buenos Aires, C1056ABI, Argentina
    Recruiting
    • · Contact08003450697
    • Federico Perez Manghi · Principal investigator
  • Centro Médico Viamonte
    Buenos Aires, C1120AAC, Argentina
    Recruiting
    • · Contact54 1149635650
    • Diego Aizenberg · Principal investigator
  • Mautalen Salud e Investigación
    Buenos Aires, C1128AAF, Argentina
    Not yet recruiting
    • · Contact541145143400
    • Jose Fretes · Principal investigator
  • Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
    Buenos Aires, C1425AGC, Argentina
    Recruiting
    • · Contact5401148019001
    • Evelyn Blanc · Principal investigator
  • Instituto Médico Catamarca IMEC
    Rosario, 2000, Argentina
    Not yet recruiting
    • · Contact3416176661
    • Natacha Maldonado · Principal investigator
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication or approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Sep 2027, 46 months after the start.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's planned 46 months is above that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2023
First posted
Nov 22, 2023
StartActual
Nov 17, 2023
Primary completionEst.
Sep 2027
CompletionEst.
Feb 2028
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Mautalen Salud e Investigación · Buenos Aires, Argentina
Oct 7, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Diablo Clinical Research, Inc. · Walnut Creek, United StatesContact person changed (no phone or email listed)
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    1 site added
    Show site
    • Mautalen Salud e Investigación · Buenos Aires, Argentina
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Diablo Clinical Research, Inc. · Walnut Creek, United StatesContact person changed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06143956
Responsible party
Sponsor
First posted
Nov 22, 2023
Start date
Nov 17, 2023
Primary completion
Sep 2027 (estimated)
Completion
Feb 2028 (estimated)
Last update
Oct 7, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@Lilly.com
1-317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Mazdutide · Eloralintide · Naperiglipron · Macupatide

Start the discussion